ERYTHROMYCIN OPHTHALMIC OINTMENT USP STERILE RX ONLY

Manufacturer
RedPharm Drug
Effective date
2024-08-07
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 21:09:41

Label at a glance#

Producterythromycin
Active ingredientERYTHROMYCIN
Label structure13 sections

Indications and uses

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheae is not established. For infants born to mothers with clinically apparent gonorrh...

Dosage and administration

In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. T...

Label contents#

Full prescribing information#

DESCRIPTION:

DESCRIPTION SECTION

Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-dideoxy-3- C-methyl-3- 0-methyl-α-L- ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D- xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione) is antibiotic produced from a strain of Streptomyces erythraeus. It has the following structural formula:

Structure Image
Structure Image

Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

Microbiology:

MICROBIOLOGY SECTION

Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitroand in clinical infections:

Streptococcus pyogenes(group A ß-hemolytic)

Alpha-hemolytic streptococci (viridans group)

Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)

Streptococcus pneumonia

Mycoplasma pneumoniae(Eaton Agent, PPLO)

Haemophilus influenzae(not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)

Treponema pallidum

Corynebacterium diphtheriae

Neisseria gonorrhoeae

Chlamydia trachomatis

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.

For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeaeor C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheaeis not established.

For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

PRECAUTIONS:

PRECAUTIONS SECTION

General:

GENERAL PRECAUTIONS SECTION

The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.

Information for Patients:

INFORMATION FOR PATIENTS SECTION

Avoid contaminating the applicator tip with material from the eye, fingers, or other source.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted.

No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.

Pregnancy:

PREGNANCY SECTION

Teratogenic effects -

TERATOGENIC EFFECTS SECTION

Pregnancy Category B.

SPL UNCLASSIFIED SECTION

Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.

Nursing Mothers:

NURSING MOTHERS SECTION

Caution should be exercised when erythromycin is administered to a nursing woman.

Pediatric Use:

PEDIATRIC USE SECTION

See INDICATIONS AND USAGEand DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.

To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

HOW SUPPLIED

HOW SUPPLIED SECTION

Sterile Erythromycin Ophthalmic Ointment USP, 5 mg/g as follows:

3.5 g (1/8 oz) tamper-evident tubes NDC 0574- 4024-35

24 x 3.5 g (1/8 oz) Hospital-Pak (for hospital use only) NDC 0574- 4024-39

Carton of fifty (50) Unit Dose 1 g tubes NDC 0574- 4024-50

Store at controlled room temperature 15°-30°C (59°-86°F). Avoid excessive heat.

Protect from freezing.

SPL UNCLASSIFIED SECTION

Manufactured For

Perrigo®

Minneapolis, MN 55427

SW700 RC J1 Rev 09-13 A

R1013

Ini 0813

Package/Label Display Panel - Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Rx Only

NDC 0574- 4024-35

Erythromycin Ophthalmic Ointment USP

NET WT 3.5 g (1/8 OZ)

STERILE

Erythromycin Ophthalmic Label.jpg
Erythromycin Ophthalmic Label.jpg

The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

C:\Users\sbrown\Pictures\serialization-template.jpg
C:\Users\sbrown\Pictures\serialization-template.jpg

Package/Label Display Panel - Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Rx Only

NDC 0574- 4024-35

Erythromycin Ophthalmic Ointment USP

NET WT 3.5 g (1/8 OZ)

STERILE

5w7-rc-erythromycin-ophthalmic-ointment-35.jpg
5w7-rc-erythromycin-ophthalmic-ointment-35.jpg

The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

serialization-template.jpg
serialization-template.jpg

Package/Label Display Panel-Hospital - Pak

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

HOSPITAL-PAK

Rx Only

NDC 0574- 4024-39

Erythromycin Ophthalmic Ointment USP

STERILE – 5 mg per Gram

For Use in High Volume Neonatal Care

HOSPITAL USE ONLY

24 x 1/8 OZ (3.5 g)

Each gram contains 5 mg of Erythromycin USP in a sterile ophthalmic base of mineral oil and white petrolatum.

5w7-rc-erythromycin-ophthalmic-ointment-39.jpg
5w7-rc-erythromycin-ophthalmic-ointment-39.jpg

The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

serialization-template.jpg
serialization-template.jpg

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - 50 Unit Doses

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Rx Only

NDC 0574- 4024-50

Erythromycin Ophthalmic Ointment USP, 0.5% (5 mg/g)

DO NOT REUSE. ONCE OPENED, DISCARD

STERILE

50 Unit Doses

Sterile Ophthalmic Ointment weighing 1 gram each.

5w7-rc-erythromycin-ophthalmic-ointment-50.jpg
5w7-rc-erythromycin-ophthalmic-ointment-50.jpg

The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

serialization-template.jpg
serialization-template.jpg

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
310149erythromycin 0.5 % (5 MG/GM) Ophthalmic OintmentPSN1
310149erythromycin 0.005 MG/MG Ophthalmic OintmentSCD1
310149erythromycin 0.5 % Ophthalmic OintmentSY1
310149erythromycin 5 MG per GM Ophthalmic OintmentSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ERYTHROMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d329c2e1-5ae8-4e64-aea0-77ecea3fa1abProduct name320250717
3b331500-3b74-bd2b-fede-d46839f2f4d5Product name620240313
fdae2630-eae0-4769-abfd-8f33d5b771b4Product name320240202
8c898317-b543-1e4e-254f-84cec2f3f57eProduct name220191002
64ae94c0-3212-d73a-92da-9e6dd85c6ebeProduct name220180118
edcfa1cf-915f-1a4c-d0aa-508cc66e70d9Product name220170816
ad75fcfd-a339-42a1-9c60-43ba2c654cfaProduct name120170810
57850177-5927-151f-e1fa-7e2ca47f81e5Product name120140508
8ee71591-1d8f-e24e-242b-bfef131e3168Product name120140508
bff5cf99-0f45-fa15-2a76-b160c3c4cc3cProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
67296-1395-1erythromycin4 g in 1 TUBEOINTMENT41

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
67296-1395ERYTHROMYCIN OINTMENT [REDPHARM DRUG]11 package rows20240808_1f1a4d57-8f3e-e9d6-e063-6294a90ab55c.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0574-4024-35GM - Gram0574-40249a87c916-2490-4c08-8964-471e41c5f45112014-07-02
0574-4024-39GM - Gram0574-40244cb5a47a-89ff-45e7-8c36-36df8f52f67512014-11-05
0574-4024-50GM - Gram0574-40240c233232-0d3a-433e-b69a-ab381af03e9e12014-07-02

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
67296-139567296-1395-1
0574-4024

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Name, UNII, Kind table
NameUNIIKind
PETROLATUM4T6H12BN9UIACT
MINERAL OILT5L8T28FGPIACT
ERYTHROMYCIN63937KV33DACTIB

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062447-001ERYTHROMYCINERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-26

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-2684e616aacf4f…
2026-08-18 06:07:402026-07A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-26caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-26011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-2631067a03dcf5…
2025-08-23 18:47 UTC2025-08A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-266a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-26fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-26b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-2603ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-262680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-265bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-26d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-26d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-2679d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-26301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-261e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMIC1983-09-268072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-265c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-265d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-264b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-2674a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-2687673890dc5c…
2021-03-12 10:30 UTC2021-03A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-265aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-268869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-263f01610625f2…
2019-09-15 20:21 UTC2019-09A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26b00525d2431f…
2019-07-19 19:46 UTC2019-07A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-266a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-261c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-269b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-263f0d92c62455…
2023-05-13 08:27 UTC2023-05A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26053a50430f4f…
2023-01-26 05:58 UTC2023-01A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-263bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-263a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062447-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1983-09-26f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062447-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062447-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062447-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062447-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062447-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062447-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062447-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A062447-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062447-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062447-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062447-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A062447-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062447-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062447-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062447-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062447-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062447-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062447-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062447-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062447-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A062447-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A062447-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062447-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062447-001AT1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A062447-001AT1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A062447-001AT1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
1f1a1ec5-dfb8-b5c0-e063-6294a90a7e071f1a4d57-8f3e-e9d6-e063-6294a90ab55c2024-08-07Adverse reactionsExact identifier
spl id: 1f1a1ec5-dfb8-b5c0-e063-6294a90a7e07
spl set id: 1f1a4d57-8f3e-e9d6-e063-6294a90ab55c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.